

Received Date: July 08, 2024

Accepted Date: July 29, 2024

Published Date: August 01, 2024

Available Online at <https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/300>

<https://doi.org/10.5281/zenodo.14583564>

Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Young Children: A Comprehensive Review

Salman Msaad Aldafar¹, Ruqayyah Abdullah Bu Mijdad², Safiah Ibrahim Alalawi³, Fatimah Jaber Al-Hammad⁴, Haidar Ibrahim Alfarhan⁵, Mohammed Abdullah Almuslim⁶, Salman Redah Alsadah⁵, Mourtada Younis Alyounis⁴, Ahmed Abdrabulridhaa Alalawi⁷, Zainab Mohammed Alshakhs⁸, Fares Mohammed Alshawaf⁹, Ali Hussain Alhamdan¹⁰, Fawaz Yousef Albattat¹¹, Mohammed Abdullah Albahrani¹², Ali Abdrabaledredha Aljaffar¹³

1. Aljaafari phc
2. AlSalmaniya PHC
3. Alsalmaniya Primary Health Care
4. Maternity and children hospital in damamm
5. Al-Aziziyah PHC
6. Sharq Albatin PHC
7. Center for Genetic Blood Diseases
8. Aljafr general hospital
9. Alfodhool phc
10. Aljesha PHC
11. Almutirfi PHC
12. Northern Alkhars phc
13. Aljaber Eye & Ent Hospital

ABSTRACT

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental disorders affecting young children. While evidence supports behavioral therapy as the first-line treatment for ADHD in children under six, medications such as stimulants are also prescribed. Medicaid, which provides health insurance to many children in the United States, has implemented prior authorization (PA) policies to regulate the use of medication for ADHD in young children. This review explores the structure and impact of Medicaid PA policies, their influence on medication usage, and the barriers and benefits associated with these policies. The role of Medicaid in promoting evidence-based care and behavioral interventions is also discussed.

Introduction

ADHD affects approximately 2% to 7% of preschool-aged children worldwide, with symptoms often impairing social, academic, and family functioning (Thomas et al., 2015). Current guidelines from the American Academy of Pediatrics (AAP) recommend parent training in behavioral management as the first-line treatment for children under six years old, with medication as a secondary option when behavioral interventions are insufficient. Despite these guidelines, studies reveal that stimulant medications, such as methylphenidate, are frequently prescribed to young children (1,2).

Medicaid programs, which cover approximately 40% of U.S. children, play a crucial role in determining access to ADHD treatments. Medicaid PA policies aim to regulate early medication use in young children by requiring documentation of prior behavioral therapy or a comprehensive evaluation. These policies are intended to ensure evidence-based treatment while preventing over-reliance on medications. However, the implementation and outcomes of these policies vary widely among states. This review examines Medicaid PA policies, their effectiveness, and their impact on ADHD treatment in young children.

1. Medicaid Prior Authorization Policies for ADHD Medications

1.1. Structure of PA Policies

PA policies typically require prescribers to document the following before approving ADHD medication for young children:

- A formal ADHD diagnosis based on diagnostic criteria (DSM-5).
- Evidence of a prior trial of behavioral therapy.

- Justification for initiating medication, such as severe symptomatology.

Some states also limit the use of specific medications in children under six or require consultations with specialists (3,4).

1.2. Goals of PA Policies

- **Promoting Evidence-Based Treatment:** By requiring prior behavioral therapy, PA policies align with AAP guidelines emphasizing non-pharmacologic interventions.
- **Preventing Overprescription:** PA aims to reduce unnecessary or premature medication use, mitigating potential adverse effects.

1.3. Variability Across States

Medicaid policies differ significantly between states, with some requiring stringent documentation and others adopting more lenient approaches. These inconsistencies create disparities in treatment access and outcomes.

2. Impact of PA Policies on ADHD Treatment

• Behavioral Therapy Utilization

Studies indicate that PA policies increase the likelihood of behavioral therapy being used as the initial treatment. However, barriers such as limited access to trained therapists and long wait times can delay treatment (5).

• Medication Use Trends

Research shows a decline in ADHD medication prescriptions in states with stricter PA requirements. While this aligns with guideline recommendations, there are concerns about undertreatment of severe cases due to administrative hurdles.

• Health Disparities

Families from low-income or rural areas, who rely heavily on Medicaid, may face greater challenges due to limited behavioral health services. These disparities can lead to delays in both behavioral therapy and medication initiation.

• Clinical Outcomes

The effectiveness of PA policies in improving clinical outcomes remains under-researched. While reducing overprescription is a positive step, ensuring timely access to appropriate care is equally critical.

3. Barriers to Effective Implementation

- **Access to Behavioral Therapy**

A shortage of behavioral health providers is a significant barrier, particularly in rural and underserved areas. Many families encounter delays in accessing therapy, which may increase reliance on medication.

- **Administrative Burden**

The PA process can be time-consuming for healthcare providers, potentially delaying necessary treatment for children with severe ADHD symptoms.

- **Parental Awareness and Education**

Parents may lack knowledge about ADHD treatment guidelines and the benefits of behavioral therapy, leading to pressure on providers to prescribe medication as a quick solution.

4. Future Directions and Recommendations

- **Increasing Access to Behavioral Therapy**

Medicaid programs should invest in expanding access to parent training programs, particularly in underserved areas. Telehealth-based behavioral therapy could also address provider shortages(6,7).

- **Streamlining PA Processes**

Simplifying PA documentation requirements and improving communication between providers and Medicaid administrators can reduce administrative barriers.

- **Monitoring and Evaluation**

Ongoing evaluation of PA policies is essential to assess their impact on treatment access, adherence to guidelines, and clinical outcomes.

- **Education and Outreach**

Educating parents and providers about evidence-based ADHD treatments can improve acceptance of behavioral interventions and adherence to PA requirements.

Conclusion

Medicaid PA policies for ADHD medications in young children aim to promote evidence-based care and prevent overprescription. While these policies align with clinical guidelines, they also present challenges, particularly for families facing systemic barriers. Addressing gaps in behavioral therapy access and streamlining PA processes are

critical to ensuring that all children receive timely and appropriate care. By fostering collaboration between policymakers, healthcare providers, and families, Medicaid can enhance the quality of ADHD treatment for young children.

References

1. Austin M, Staats N, Burgdorf L. Onset and Prevalence of ADHD - ADHD. Attention Deficit Hyperactivity Disorder. 2007.
2. The ADHD explosion: myths, medication, money, and today's push for performance. Choice Reviews Online. 2014;52(04).
3. Hulkower RL, Kelley M, Cloud LK, Visser SN. Medicaid prior authorization policies for medication treatment of attention-deficit/hyperactivity disorder in young children, United States, 2015. Public Health Reports. 2017;132(6).
4. R.L. H, M. K, L.K. C, S.N. V. Medicaid prior authorization policies for medication treatment of attention-deficit/hyperactivity disorder in young children, United States, 2015. Public Health Reports. 2017;132(6).
5. French B, Sayal K, Daley D. Barriers and facilitators to understanding of ADHD in primary care: a mixed-method systematic review. Eur Child Adolesc Psychiatry. 2019;28(8).
6. Myers KM, Valentine JM, Melzer SM. Child and adolescent telepsychiatry: Utilization and satisfaction. Telemedicine and e-Health. 2008;14(2).
7. Myers KM, Valentine JM, Melzer SM. Feasibility, acceptability, and sustainability of telepsychiatry for children and adolescents. Psychiatric Services. 2007;58(11).